Codexis Inc. (CDXS)
NASDAQ: CDXS
· Real-Time Price · USD
2.78
-0.03 (-1.07%)
At close: Jul 03, 2025, 3:43 PM
2.71
-2.52%
After-hours: Jul 03, 2025, 04:57 PM EDT
Codexis Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Sitagliptin Enzyme Revenue | 2.5M | 27.24M | 1.6M | 3.05M | 2.3M | 57K | 2.73M |
| Sitagliptin Enzyme Revenue Growth | -90.82% | +1602.31% | -47.61% | +32.61% | +3940.35% | -97.92% | n/a |
| Research and Development Revenue Revenue | 22.56M | n/a | 1.61M | 2.8M | n/a | n/a | n/a |
| Research and Development Revenue Revenue Growth | n/a | n/a | -42.39% | n/a | n/a | n/a | n/a |
| Product Revenue | 36.79M | n/a | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas Revenue | 21.28M | 13.73M | 17M | 23.48M | 24.35M | 13.04M | 15.37M | 5.64M | 3.58M | 1.03M | 919K | 11.01M | 51.71M |
| Americas Revenue Growth | +54.94% | -19.22% | -27.60% | -3.58% | +86.76% | -15.17% | +172.57% | +57.60% | +248.73% | +11.64% | -91.65% | -78.72% | n/a |
| Asia Pacific Revenue | 27.71M | 33.5M | 65.05M | 61.09M | 19.26M | 37.13M | 22.36M | 6.17M | 3.84M | 963K | 1.44M | n/a | n/a |
| Asia Pacific Revenue Growth | -17.30% | -48.50% | +6.49% | +217.21% | -48.14% | +66.06% | +262.71% | +60.71% | +298.34% | -32.89% | n/a | n/a | n/a |
| China Revenue | 9.8M | 20.3M | 56.54M | 20.19M | n/a | n/a | n/a | 13.22M | 21.31M | 24.8M | 16.14M | n/a | n/a |
| China Revenue Growth | -51.72% | -64.10% | +180.08% | n/a | n/a | n/a | n/a | -37.98% | -14.06% | +53.66% | n/a | n/a | n/a |
| Emea Revenue | 10.36M | 22.91M | n/a | n/a | n/a | n/a | n/a | 15.47M | n/a | n/a | n/a | n/a | n/a |
| Emea Revenue Growth | -54.78% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| India Revenue | 7.3M | 500K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| India Revenue Growth | +1360.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ireland Revenue | 1.8M | 11.1M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ireland Revenue Growth | -83.78% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Singapore Revenue | 6.2M | 13.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Singapore Revenue Growth | -54.74% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Switzerland Revenue | 3.4M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Switzerland Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 21.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 12.36M | 13.05M | 13.57M | 15.45M | 12.64M | 10.97M | 12.3M | 13.37M | 15.4M | 12.31M | 13.5M | 10.66M | 15.71M | 11.72M | 13.41M | 12.79M | 11.4M | 8.74M | 8.8M | 8.52M | 8.99M | 7.32M | 7.87M | 7.9M | 8.41M | 6.81M | 7.34M | 7.39M | 7.75M | 7.87M | 7.99M | 6.55M | 6.61M | 6.97M | 5.23M | 6.42M | 6.8M | 6.03M | 5.42M | 5.3M | 5.58M |
| Selling, General, and Administrative Revenue Growth | -5.31% | -3.83% | -12.19% | +22.25% | +15.24% | -10.84% | -7.95% | -13.21% | +25.05% | -8.78% | +26.68% | -32.15% | +33.97% | -12.56% | +4.78% | +12.26% | +30.40% | -0.64% | +3.23% | -5.20% | +22.77% | -6.95% | -0.34% | -6.17% | +23.64% | -7.33% | -0.69% | -4.53% | -1.54% | -1.53% | +22.04% | -0.91% | -5.20% | +33.26% | -18.55% | -5.62% | +12.88% | +11.28% | +2.25% | -5.06% | n/a |
| Research and Development Revenue | 1.48M | 12.1M | 11.51M | 10.39M | 10.21M | 11.23M | 13.66M | 17.33M | 16.66M | 19.69M | 21.82M | 19.09M | 19.5M | 16.36M | 15.16M | 12.83M | 11.57M | 10.36M | 12.01M | 10.85M | 10.97M | 8.87M | 8.71M | 8.27M | 8.02M | 7.51M | 7.92M | 7.37M | 7.18M | 9.42M | 8.05M | 6.35M | 5.84M | 5.96M | 5.47M | 5.11M | 5.69M | 5.22M | 4.99M | 5.17M | 5.29M |
| Research and Development Revenue Growth | -87.73% | +5.16% | +10.70% | +1.75% | -9.08% | -17.77% | -21.18% | +4.08% | -15.41% | -9.77% | +14.31% | -2.11% | +19.22% | +7.86% | +18.24% | +10.85% | +11.74% | -13.78% | +10.66% | -1.04% | +23.61% | +1.85% | +5.28% | +3.22% | +6.70% | -5.10% | +7.42% | +2.67% | -23.78% | +16.91% | +26.89% | +8.72% | -2.10% | +9.09% | +6.94% | -10.09% | +9.01% | +4.45% | -3.40% | -2.32% | n/a |